Abstract
Aims/hypothesis
The Cost of Diabetes in Europe-Type II study is the first coordinated attempt to assess the total costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. Although gaining a clearer understanding of the economics of diabetes was the goal of the study, a secondary objective was to consider the impact of Type II diabetes from the patient’s perspective.
Methods
The protocol included a health status questionnaire completed by the patient, the EQ-5D instrument, which assessed health-related quality of life by asking the patient to consider five dimensions: mobility, self-care, usual activities, pain and discomfort, as well as anxiety and depression.
Results
A total of 4189 patients in five of the eight countries completed the EQ-5D questionnaire for assessing the quality of life. Overall, patients with Type II diabetes reported scores between good and fair states of health, although the average score (0.69) was lower than that of the similarly aged, healthy population in the United Kingdom. However, these values were higher (0.76) in Type II diabetic patients without complications. The onset of either microvascular or macrovascular complications adversely affected quality of life (0.69 and 0.69, respectively), and the presence of both types of complications further reduced the quality of life score to 0.59. Treatment with insulin was also associated with a reduced quality of life (0.62). Multivariate analysis showed that the following factors, in order of importance, independently pre-dict a poorer quality of life: gender, complications, treatment type, age, obesity and hyperglycaemia.
Conclusion/interpretation
The results showed that health-related quality of life is an important issue in Type II diabetes and this decreases with disease progression. The implication for policy-makers is that reducing or preventing the complications of diabetes is the key to improving patient quality of life.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- EQ-50:
-
Euroqol 5 dimensions (questionnaire)
- CODE2:
-
Cost of Diabetes in Europe Type 2
- UKPDS:
-
United Kingdom Prospective Diabetes Study
- HRQoL:
-
health-related quality of life
References
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025. Diabetes Care 21:1414–1431
Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA (1989) The economic costs of non-insulin-dependent diabetes mellitus. JAMA 262:2708–2713
Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in Type 2 diabetes mellitus. Arch Intern Med 159:1873–1880
Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type 2 diabetes. Diabetologia supplement (this issue)
UK Prospective Diabetes Study group (1999) Quality of life in Type 2 diabetes patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. Diabetes Care 22:1125–1136
Shen W, Kotsanos JG, Huster WJ, Mathias SD, Andrejasich CM, Patrick DL (1999) Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire. Med Care 37:AS45–AS66
Hermann BP, Vickrey B, Hays RD et al. (1996) A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 25:113–118
Brooks B with the EuroQoL Group (1996) EuroQoL: The current state of play. Health Policy 37:52–72
EuroQoL User Guide (1996) Euroqol Business Management Group, Rotterdam
Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the Economic Evaluation of Healthcare Programmes, 2nd edn. Oxford University Press, Oxford
Jonsson B (2000) Revealing the cost of Type 2 diabetes in Europe. Diabetologia supplement (this issue)
Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741
World Health Organisation (1948) World Health Organisation constitution. In: Basic Documents. World Health Organisation, Geneva New Eng J Med 334(13):835–840
Testa MA, Simonson DC (1996) Assessment of quality-of-life outcomes. N Engl J Med:835–840
Assal JP (1995) Cost-effectiveness of diabetes education. Pharmacoeconomics 8:68–71
Jacobson AM (1996) The psychological care of patients with insulin dependent diabetes mellitus. N Engl J Med 334:1249–1253
Hörnquist JO, Wikby A, Stenström U, Andersson PO, Âkerlind I (1995) Type II diabetes and quality of life. Phar-macoeconomics 8:12–16
Littlefield C, Rodin GM, Murray MA, Craven JL (1990) Influence of functional impairment and social support on depressive symptoms in persons with diabetes. Health Psychol 9:737–749
Cox DJ, Gonder-Frederick L (1992) Major developments in behavioural diabetes research. J Consult Clin Psychol 60:628–638
Cunha-Vaz J (1998) Lowering the risk of visual impairment and blindness. 15:S47–S50
Kumar S, Ashe HA, Parnell LN et al. (1994) The prevalence of foot ulceration and its correlates in Type 2 diabetic patients: a population-based study. Diabet Med 11:480–484
Pibernik-Okanoviae M, Szabo S, Metelko Z (1998) Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 14:201–207
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Koopmanschap wrote on behalf of the CODE-2 Advisory Board
Rights and permissions
About this article
Cite this article
Koopmanschap, M. Coping with Type II diabetes: the patient’s perspective. Diabetologia 45 (Suppl 1), S21–S22 (2002). https://doi.org/10.1007/s00125-002-0861-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-002-0861-2